diabetes
Novo rebuked after diabetes promotion breaches Code
December 16, 2010Medical Communications ABPI, ABPI Code of Practice, Grunenthal, Napp Pharmaceuticals, Novo Nordisk, PMCPA, diabetes, diabetes drug marketing, lilly
Novo Nordisk been ‘named and shamed’ in health trade journal advertisements this week for breaching the ABPI Code of Practice. …
Merck acquires innovative insulin firm SmartCells
December 3, 2010Research and Development Merck, Merck & Co, SmartCells, diabetes, insulin
Merck has bolstered its early stage diabetes portfolio with the acquisition of SmartCells, a private pharma firm that’s developing a …
Digital Pharma: Diabetes video goes viral
November 16, 2010Medical Communications, Sales and Marketing Diabetes Hands Foundation, Digital Pharma blog, Roche, diabetes, viral video, youtube
An online video encouraging diabetics to test their blood sugar levels has passed 117,000 views on YouTube in just over …
Lilly bolsters diagnostics presence with Avid acquisition
November 9, 2010Research and Development Alzheimer's disease, Alzheimer’s disease, Avid Radiopharma, Eli Lilly, diabetes, emagacestat, florbetapir, lilly
Eli Lilly has acquired specialist diagnostics firm Avid Radiopharma in a deal that will bolster its diagnostics business. Philadelphia-based Avid …
Digital Pharma: Diabetes patients and Facebook
November 3, 2010Medical Communications Digital Pharma blog, Facebook, diabetes, patient information, social networking
A quarter of comments on the 15 largest Facebook communities for diabetes patients are promotional – generally for non-FDA approved …
Lilly to open diabetes research centre in China
November 2, 2010Research and Development China, Eli Lilly & Co, Lilly Research Laboratories in China, diabetes, lilly
The march of foreign pharma companies into China is to continue with Eli Lilly and Co’s opening of a diabetes …
Lilly suspends late-stage trials of diabetes drug Protege
October 22, 2010Research and Development, Sales and Marketing MacroGenics, Protege, diabetes, lilly, type I diabetes
Eli Lilly and its partner MacroGenics have suspended phase III trials of their investigational type I diabetes drug Protege after …
Novo Nordisk invests $73m to boost diabetes drug production
October 8, 2010Manufacturing and Production Novo Nordisk, diabetes, insulin
Novo Nordisk has announced another major expansion of its manufacturing capacity for diabetes products, setting aside $73 million to expand …
AZ-BMS diabetes drug impresses in phase III trials
October 1, 2010Research and Development, Sales and Marketing AstraZeneca, BMS, dapagliflozin, diabetes
AstraZeneca and Bristol Myers Squibb’s potential first-in-class diabetes drug dapagliflozin has shown strong results in a late stage trial. It …
Lixisenatide shaping up to rival Victoza
September 22, 2010Research and Development Lixisenatide, Sanofi-Aventis, diabetes
Data for Sanofi-Aventis’ injectable lixisenatide suggests it could rival Novo Nordisk’s drug Victoza.Lixisenatide is a once-daily GLP-1 receptor agonist, and …
Transition drops new diabetes drug
September 20, 2010Research and Development Transition Therapeutics, diabetes, lilly
Transition Therapeutics is to abandon trials of its new diabetes treatment TT-223 following disappointing trial results. The Canadian biopharma company …
FDA launches safety review of Actos
September 20, 2010Sales and Marketing Actos, Takeda, diabetes
A new safety review of Takeda’s diabetes drug Actos has been launched by the FDA after a long-term study suggested …
Digital Pharma: Novo launches insulin dosing app
September 17, 2010Medical Communications, Sales and Marketing Digital Pharma blog, Novo Nordisk, app, diabetes, iphone
Novo Nordisk has launched an iPhone app for US healthcare professionals that enables to them look up dosing guidelines for …
Novo expands diabetes research in China
September 16, 2010Research and Development China, Novo Nordisk, diabetes
Diabetes is at the core of Novo Nordisk’s latest investment in China, where the company plans to more than double …
GSK accused of Avandia cover-up
July 14, 2010Sales and Marketing Avandia, GlaxoSmithKline, diabetes
The ongoing battle over GlaxoSmithKline’s diabetes drug Avandia has taken another turn with US senators accusing the company of a …
Latest content
